Tacrolimus 0.1% for Vitiligo: Efficacy by Zone (Face/Neck vs Trunk vs Acral) — Evidence Overview
Key Takeaways Face/neck respond fastest: perifollicular islands in 4–8 weeks, meaningful F-VASI drops by 8–12 weeks—best as nightly monotherapy or […]
calcineurin inhibitors
Vitiligo Combination Algorithms: NB-UVB / Excimer 308 + Topicals (Steroids, Calcineurin Inhibitors, JAK) by Site
Key Takeaways Face/neck: NB-UVB or excimer + tacrolimus 0.1% is first-line; consider label-eligible topical JAK for added speed in limited
Excimer 308 nm for Focal Vitiligo (Face/Neck): Protocols, Response Kinetics, and Combinations
Key Takeaways Targeted therapy ideal for focal lesions, active edges, and facial/neck sites; enables high local dose while sparing uninvolved
NB-UVB 311 nm in Nonsegmental Vitiligo: Cohort Outcomes, Protocols, and Site-Specific Response
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo; best outcomes on face/neck, slower on acral sites. Typical schedule 2–3×/week for 24–48
NB-UVB 311 nm in Nonsegmental Vitiligo: Cohort Outcomes, Protocols, and Safety (n≈150–200)
Key Takeaways Backbone therapy for generalized/nonsegmental vitiligo with best responses on face/neck; acral lesions remain hardest. Typical schedules: 2–3×/week, incremental
Excimer 308 nm for Focal Vitiligo: Face/Neck Outcomes, Parameters, and Safety
Key Takeaways Excimer 308 nm is well suited for localized/focal lesions, particularly on the face and neck, enabling targeted high-fluence delivery
Autoimmunity in Vitiligo: IFN-γ/CXCL9–10 Axis, Tissue-Resident Memory T Cells, and the Koebner Phenomenon
Key Takeaways Vitiligo is driven by cytotoxic, melanocyte-reactive T cells orchestrated by an IFN-γ → CXCL9/10 → CXCR3 chemokine circuit.